Anti-Canine PD-L1 (34091)
Anti-Canine PD-L1 (34091)
Product No.: 34091
- -
- -
Clone JC071 Target Canine PD-L1 Formats AvailableView All Product Type Monoclonal Alternate Names Programmed Death Ligand 1, B7-H1, PD-L1, CD274 Isotype Mouse IgG1 Applications FACS , IHC , Inhibition |
Data
Inhibition of PD-1 and PD-L1 Interaction JC071 antibody added to ELISA plates coated with PD-L1 followed by the addition of biotinylated PD-1 and streptavidin-HRP. JC071 antibody blocked binding of PD-1 to PD-L1 as compared with binding of PD-1 to PD-L1 in the presence of culture medium or PBS.
Courtesy of Dr. JW Choi, University of California, Davis.
Flow CytometryDetection of PD-L1 expression on CLGL-90 cells (Chronic Large Granular Lymphocytic-90) stained with JC071 (dark gray) vs. mouse IgA isotype control (light gray).
Courtesy of Dr. JW Choi, University of California, Davis.
- -
- -
Antibody DetailsProduct DetailsReactive Species Canine Host Species Mouse Immunogen Recombinant extracellular domain of canine PD-L1 fused with the Fc domain of human IgG1 expressed in D. melanogaster S2 cells. Product Concentration Lot Specific Formulation PBS, pH 7.4. State of Matter Liquid Product Preparation Purified by Protein G affinity chromatography Storage and Handling This antibody is stable for at least one (1) year at -20°C to-70°C. Store in appropriate aliquots to avoid multiple freeze-thaw cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco Flow cytometry Detection of PD-L1 expression on CLGL-90 cells (Chronic Large Granular Lymphocytic-90) stained with JC071 (dark gray) vs. mouse IgA isotype control (light gray).
Endusers should determine optimal antibody concentrations for their applications. Inhibition of PD-1 and PD-L1 Interaction JC071 antibody added to ELISA plates coated with PD-L1 followed by the addition of biotinylated PD-1 and streptavidin-HRP. JC071 antibody blocked binding of PD-1 to PD-L1 as compared with binding of PD-1 to PD-L1 in the presence of culture medium or PBS. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Mouse Monoclonal Antibody specific to Canine PD-L1 Background Each year, thousands of dogs are diagnosed with cancer. Canine cancers bear many of the
hallmarks of human cancers including tissue location, tumor progression, and response to
chemotherapy and radiation. Unfortunately, canine lymphocyte populations are not as well
defined as human lymphocytes, and reagents that target immune checkpoint pathways are not
yet widely available for veterinary research. Interruption of the programmed death 1 (PD-1) /
programmed death ligand 1 (PD-L1) pathway is an established and effective therapeutic strategy
in human oncology and may be effective for treating canine cancers as well.
Research Area Cancer . Costimulatory Molecules . Immunology References & CitationsChoi JW et al. 2020 Development of canine PD-1/PD-L1 specific monoclonal antibodies and
amplification of canine T cell function. PLoS One. 2020; 15(7): e0235518. |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
